Summary
A multicenter study for monitoring antimicrobial drug resistance in clinical isolates of the familyEnterobacteriaceae, Pseudomonas aeruginosa, Staphylococcus andEnterococcus species in central Europa conducted by the Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy has been ongoing since 1975. Between 1975 and 1995 susceptibility data on almost 60,000 bacteria, which were isolated and sampled under a common protocol by laboratories from Austria, Germany and Switzerland, were collected. These bacterial isolates were known by the respective investigators to have caused infections. From 1975 to the mid-80s none of the bacterial species examined showed an increase in resistance. The frequency of resistance in klebsiellae andStaphylococcus aureus to some antibiotics even declined. In 1990 and particularly in 1995, a clear increase in resistance for a number of antibiotic-organism pairs was observed. Resistance rates of fluoroquinolones increased in all species under investigation. InEscherichia coli the increase of resistance to ampicillin, co-trimoxazole and gentamicin was remarkable. Resistance to imipenem increased inP. aeruginosa. Resistance to cephalosporins, on the other hand, remained largely unchanged in gram-negative bacilli. Between 1990 and 1995, the prevalence of oxacillin resistance increased from 1.7 to 12.9% inS. aureus and from 15.8 to 55.8% in coagulase-negative staphylococci, whereas staphylococcal and enterococcal resistance to glycopeptides was still rare.
Similar content being viewed by others
References
Gold, H. S., Moellering, R. C., Jr. Antimicrobial-drug resistance. N. Engl. J. Med. 335 (1996) 1445–1453.
Tenover, F. C., Hughes, J. M.: The challenge of emerging infectious diseases—development and spread of multiply-resistant bacterial pathogens. JAMA 275 (1996) 300–304.
Lederberg, J., Shope, R. E., Oaks, S. C. Jr. (eds.): Emerging infections: microbial threats to health in the United States. National Academy Press, Washington, D.C. 1992.
Kresken, M., Wiedemann, B.: Die Epidemiologie der Resistenz bei Bakterien und ihre-Bedeutung für die Wirksamkeit von Chemotherapeutika. Fortschr. Antimikrob. Antineoplast. Chemother. 6–6 (1987) 869–1063.
DIN Deutsches Institut für Normung e. V.: Methoden zur Empfind-lichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika. DIN 58940, Teil 3—Beiblatt 1 und Teil 4—Beiblatt 1. Beuth Verlag, Berlin 1998.
Du Bois, S. K., Marriott, M. S., Amyes, S. G. B.: TEM- and SHV-derived extended β-lactamases: relationship between selection, structure and function. J. Antimicrob. Chemother. 35 (1995) 7–22.
Monnet, D. L., Archibald, L. K., Phillips, L., Tenover, F. C., McGowan, J. E. Jr., Gaynes, R. P., the Intensive Care Antimicrobial Resistance Epidemiology Project and the National Infections Surveillance System Hospitals: Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modelling. Infect. Control Hosp. Epidemiol. 19 (1998) 388–394.
Feinman, S.: Antibiotics in animal feed—drug resistance revisited. ASM News 64 (1998) 24–30.
Author information
Authors and Affiliations
Consortia
Additional information
Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy (participating centers in 1995): R. Lütticken (Universitätsklinikum Aachen); I. Heinzer (Kantonsspital Aarau); R. Frei (Kantonsspital Basel); E. Halle (Universitätsklinikum Charité Berlin); H. Langmaack (Krankenhaus Berlin-Moabit); J. Wagner (Universitätsklinikum Benjamin Franklin Berlin); C. Breer, J. Looney (Universitätsklinikum Bern); B. Wiedemann (Universitätsklinikum Bonn); U. Warweg (Thüringer Medizinal-, Lebensmittel- und Veterinäruntersuchungsamt Erfurt); G. Breitfellner (Landeskrankenhaus Feldkirch); V. Brade, V. Schäfer (Universitätsklinikum Frankfurt): H. Krüpe (Städtisches Klinikum Fulda); R. Auckenthaler, B. Peppey, P. Rohner (Hopital Cantonal Universitaire Genève); M.-E. Höpken (Niedersächsisches Landesgesundheitsamt Hannover); F. Allerberger (Bundesstaatl. Bakteriolog.-Serolog. Untersuchungsanstalt Innsbruck); W. Pfister, E. Straube (Universitätsklinikum Jena); R. Ringelmann (Städtisches Klinikum Karlsruhe); U. Ullmann (Universitätsklinikum Kiel); R. Gross, G. Peters (Universitätsklinikum Münster); J. Breer, A. C. Rodloff (Universitätsklinikum Leipzig); C. Jebelean, H. Mittermayer (Krankenhaus der Elisabethinnen Linz); H. P. Marder, J. Munzinger (Kantonsspital Luzern); T. Krause, W. Mannheim, R. Mutters (Universitätsklinikum Marburg); K. Fabricius (Städtisches Klinikum Offenbach); H. Schmidt, M. Wolter (Universitätsklinikum Rostock); H. H. Siegrist (Institut neuchatelois de microbiologie La Chaux-de-Fonds); H. P. Rohr (Institut für Gesundheit und Umwelt Saarbrücken); P. Ehring, H. Werner (Universitätsklinikum Tübingen); R. Marre (Universitätsklinikum Ulm); M. Rotter (Universitätsklinikum Wien); G. Wewalka (Bundesstaatl. Bakteriolog. Serolog. Untersuchungsamt Wien); H. Grimm (Labor Dr. Gärtner Weingarten); F. H. Kayser (Universitätsklinikum Zürich).
Rights and permissions
About this article
Cite this article
Kresken, M., Hafner, D. & the Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975–1995. Infection 27 (Suppl 2), S2–S8 (1999). https://doi.org/10.1007/BF02561661
Issue Date:
DOI: https://doi.org/10.1007/BF02561661